Recent patents in the field of radioprotector development: Opportunities and challenges

Recent Patents on Biotechnology

Volumn 7, Issue 3, 2013, Pages 219-227

  Suman, Shubhankar ^a   Jain, Saurabh ^b   Chandna, Sudhir ^c  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RANI DURGAVATI UNIVERSITY   (India)

^c INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

Acute radiation syndrome; Radiation countermeasure; Radiation mitigation; Radiation protection

Indexed keywords

DRUG PRODUCTS; IONIZING RADIATION; PATENTS AND INVENTIONS; RADIATION PROTECTION;

ACUTE RADIATION SYNDROME; DEVELOPMENT APPROACH; DRUG DEVELOPMENT; DRUG DISCOVERY; FUNDINGS; RADIATION COUNTERMEASURE; RADIATION MITIGATION; RADIATION-INDUCED; RADIOPROTECTIVE AGENTS; RADIOPROTECTORS;

MOLECULES;

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AEOL 10150; AMIFOSTINE; ANDROSTENEDIOL; ANTIINFECTIVE AGENT; ASCORBIC ACID; BIO 300; CBLB601; CIPROFLOXACIN; ELECTROLYTE; ENTOLIMOD; EPOGEN ALPHA; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GENISTEIN; GLUTATHIONE; HOMSPERA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 3; INTERLEUKIN 6; KERATINOCYTE GROWTH FACTOR; PALBOCICLIB; PLERIXAFOR; PRC 210; RADIOMITIGATOR; RADIOPROTECTIVE AGENT; RECILISIB; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; REMESTEMCEL L; RLIP 76; ROMYELOCEL L; RX 100; SGX 201; STEM CELL FACTOR; TETRACYCLINE; THROMBOPOIETIN; TOCOPHEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE RADIATION SYNDROME; ARTICLE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HEMATOPOIETIC SYSTEM; HUMAN; MULTIPLE ORGAN FAILURE; NEUTROPENIA; NONHUMAN; PATENT; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIATION INJURY; RADIATION PROTECTION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANIMALS; BIOTECHNOLOGY; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; PATENTS AS TOPIC; RADIATION-PROTECTIVE AGENTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84891510188     PISSN: 18722083     EISSN: None     Source Type: Journal    
DOI: 10.2174/18722083113076660012     Document Type: Article

References (65)

1. th ed. Philadelphia: J.B. Lippincott Company 2006.
2. Small GR, Wells RG, Schindler T, Chow BJ, Ruddy TD. Advances in Cardiac SPECT and PET Imaging: Overcoming the Challenges to Reduce Radiation Exposure and Improve Accuracy. Can J Cardiol 2012; 29(3):275-84.
3. Haffty BG, Lee C. Exposure to diagnostic levels of radiation prior to age 30 increases the risk of breast cancer in BRCA1/2 carriers. Evid Based Med 2013; 18(4):e40.
4. Chawla SC, Federman N, Zhang D, et al. Estimated cumulative radiation dose from PET/CT in children with malignancies: a 5-year retrospective review. Pediatr Radiol 2010; 40: 681-6.
5. Hendee WR, O'Connor MK. Radiation risks of medical imaging: separating fact from fantasy. Radiology 2012; 264: 312-21.
6. McRobbie DW. Occupational exposure in MRI. Br J Radiol 2012; 85: 293-312.
7. Barrett B, Stiles M, Patterson J. Radiation risks: critical analysis and commentary. Prev Med 2012; 54: 280-2.
8. Christodouleas JP, Forrest RD, Ainsley CG, Tochner Z, Hahn SM, Glatstein E. Short-term and long-term health risks of nuclearpower-plant accidents. N Engl J Med 2011; 364: 2334-41.
9. Freshwater DA. Effects of nuclear weapons on the gastrointestinal system. J R Army Med Corps 2004; 150: 17-21.
10. Burkart W. Radioepidemiology in the aftermath of the nuclear program of the former Soviet Union: unique lessons to be learnt. Radiat Environ Biophys 1996; 35: 65-73.
11. Stewart A. The role of epidemiology in the detection of harmful effects of radiation. Environ Health Perspect 2000; 108: 93-6.
12. Tsushima H, Iwanaga M, Miyazaki Y. Late effect of atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes. Int J Hematol 2012; 95: 232-8.
13. Mettler FA Jr, Voelz GL. Major radiation exposure-what to expect and how to respond. N Engl J Med 2002; 346: 1554-61.
14. Meineke V, Fliedner TM. Radiation-induced multi-organ involvement and failure: challenges for radiation accident medical management and future research. BJR Suppl 2005; 27: 196-200.
15. Gourmelon P, Marquette C, Agay D, Mathieu J, Clarençon D. Involvement of the central nervous system in radiation-induced multi-organ dysfunction and/or failure. BJR Suppl 2005; 27: 62-8.
16. Jackson WL Jr, Gallagher C, Myhand RC, Waselenko JK. Medical management of patients with multiple organ dysfunctions arising from acute radiation syndrome. BJR Suppl 2005; 27: 161-8.
17. Alexander GA, Swartz HM, Amundson SA, et al. BiodosEPR-2006 Meeting: Acute dosimetry consensus committee recommendations on biodosimetry applications in events involving uses of radiation by terrorists and radiation accidents. Radiat. Meas 2007; 42: 972-96.
18. Dainiak N, Gent RN, Carr Z, et al. First global consensus for evidence-based management of the hematopoietic syndrome resulting from exposure to ionizing radiation. Disaster Med Public Health Prep 2011; 5(3): 202-12.
19. Dainiak N, Gent RN, Carr Z, et al. Literature review and global consensus on management of acute radiation syndrome affecting nonhematopoietic organ systems. Disaster Med Public Health Prep 2011; 5: 183-5201.
20. Waselenko JK, MacVittie TJ, Blakely WF, et al. Strategic National Stockpile Radiation Working Group. Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med 2004; 140: 1037-51.
21. Sagar J, Chaib B, Sales K, Winslet M, Seifalian A. Role of stem cells in cancer therapy and cancer stem cells: a review. Cancer Cell Int 2007; 7:9.
22. Drouet M, Hérodin F. Radiation victim management and the haematologist in the future: time to revisit therapeutic guidelines? Int J Radiat Biol 2010; 86: 636-48.
23. Berger ME, Christensen DM, Lowry PC, Jones OW, Wiley AL. Medical management of radiation injuries: current approaches. Occup Med (Lond) 2006; 56: 162-72.
24. Herodin F, Drouet M. Cytokine-based treatment of accidentally irradiated victims and new approaches. Experimental Hematology 2005; 33: 1071-80.
25. Herodin F, Bourin P, Mayol JF, Lataillade JJ, Drouet M. Short-term injection of antiapoptotic cytokine combinations soon after lethal gamma-irradiation promotes survival. Blood 2003; 101: 2609-16.
26. Fry TJ, Sinha M, Milliron M, et al. Flt3 ligand enhances thymicdependent and thymic-independent immune reconstitution. Blood 2004; 104: 2794-800.
27. Hudak S, Leach MW, Xu Y, Menon S, Rennick D. Radioprotective effects of flk2/flt3 ligand. Experimental Hematology 1998; 26: 515-22.
28. Singh VK, Ducey EJ, Brown DS, Whitnall MH. A review of radiation countermeasure work ongoing at the Armed Forces Radiobiology Research Institute. Int J Radiat Biol 2012; 88: 296-310.
29. Daly A. Remestemcel-L, the first cellular therapy product for the treatment of graft-versus-host disease. Drugs Today (Barc) 2012; 48: 773-83.
30. Lange C, Brunswig-Spickenheier B, Cappallo-Obermann H, et al. Radiation rescue: mesenchymal stromal cells protect from lethal irradiation. PLoS One 2011 5; 6: e14486.
31. Mannon PJ. Remestemcel-L: human mesenchymal stem cells as an emerging therapy for Crohn's disease. Expert Opin Biol Ther 2011; 11: 1249-56.
32. Grdina DJ, Shigematsu N, Dale P, Newton GL, Aguilera JA, Fahey RC. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action. Carcinogenesis 1995; 16(4): 767-74.
33. Rose PG. Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma. Semin Oncol 1996; 23: 83-9.
34. Kligerman MM, Turrisi AT, Urtasun RC, et al. Final report on phase I trial of WR-2721 before protracted fractionated radiation therapy Int J Radiat Oncol Biol Phys 1988; 14: 1119-22.
35. Citrin D, Cotrim AP, Hyodo F, Baum BJ, Krishna MC, Mitchell JB. Radioprotectors and mitigators of radiation-induced normal tissue injury. Oncologist 2010; 15(4): 360-71.
36. Epperly MW, Franicola D, Shields D, et al. Screening of antimicrobial agents for in vitro radiation protection and mitigation capacity, including those used in supportive care regimens for bone marrow transplant recipients. In Vivo 2010; 24: 9-19.
37. Grace MB, Singh VK, Rhee JG, Jackson WE 3rd, Kao TC, Whitnall MH. 5-AED enhances survival of irradiated mice in a G-CSFdependent manner, stimulates innate immune cell function, reduces radiation-induced DNA damage and induces genes that modulate cell cycle progression and apoptosis. J Radiat Res 2012; 53(6):840-53.
38. Stickney DR, Groothuis JR, Ahlem C, et al. Preliminary clinical findings on NEUMUNE as a potential treatment for acute radiation syndrome. J Radiol Prot 2010; 30(4):687-98.
39. Singh VK, Grace MB, Jacobsen KO, et al. Administration of 5-androstenediol to mice: pharmacokinetics and cytokine gene expression. Exp Mol Pathol 2008; 84(2):178-88.
40. Xiao M, Inal CE, Parekh VI, Chang CM, Whitnall MH. 5-Androstenediol promotes survival of gamma-irradiated human hematopoietic progenitors through induction of nuclear factorkappaB activation and granulocyte colony-stimulating factor expression. Mol Pharmacol 2007; 72(2):370-9.
41. Burdelya LG, Krivokrysenko VI, Tallant TC, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008; 320(5873):226-30.
42. Buwitt-Beckmann U, Heine H, Wiesmuller KH, et al. Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur J Immunol 2005; 35(1):282-9.
43. Shakhov AN, Singh VK, Bone F, et al. Prevention and mitigation of acute radiation syndrome in mice by synthetic lipopeptide agonists of Toll-like receptor 2 (TLR2). PLoS One 2012; 7(3): e33044.
44. Suman S, Datta K, Doiron K, et al. Radioprotective Effects of ON 01210.Na upon Oral Administration. J Radiat Res 2012; 53(3): 368-76.
45. Suman S, Maniar M, Fornace AJ Jr, Datta K. Administration of ON 01210. Na after exposure to ionizing radiation protects bone marrow cells by attenuating DNA damage response. Radiat Oncol 2012; 7: 6-14.
46. Ghosh SP, Kulkarni S, Perkins MW, et al. Amelioration of radiation-induced hematopoietic and gastrointestinal damage by Ex-RAD® in mice. J Radiat Res 2012; 53(4):526-36.
47. Ghosh SP, Perkins MW, Hieber K, et al. Radiation protection by a new chemical entity, Ex-RadTM: efficacy and mechanisms. Radiat Res 2009; 171(2):173-9.
48. Valachovicova T, Slivova V, Bergman H, Shuherk J, Sliva D. Soy isoflavones suppress invasiveness of breast cancer cells by the inhibition of NF-kappaB/AP-1-dependent and-independent pathways. Int J Oncol 2004; 25(5):1389-95.
49. Zenk JL. New therapy for the prevention and prophylactic treatment of acute radiation syndrome. Expert Opin Investig Drugs 2007; 16(6):767-70.
50. Calveley VL, Jelveh S, Langan A, et al. Genistein can mitigate the effect of radiation on rat lung tissue. Radiat Res 2010; 173(5):602-11.
51. Singh VK, Grace MB, Parekh VI, Whitnall MH, Landauer MR. Effects of genistein administration on cytokine induction in wholebody gamma irradiated mice. Int Immunopharmacol 2009; 9(12):1401-10.
52. Zhou Y, Mi MT. Genistein stimulates hematopoiesis and increases survival in irradiated mice. J Radiat Res 2005; 46(4):425-33.
53. Landauer MR, Srinivasan V, Seed TM. Genistein treatment protects mice from ionizing radiation injury. J Appl Toxicol 2003; 23(6):379-85.
54. Johnson SM, Torrice CD, Bell JF, et al. Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest 2010; 120(7):2528-36.
55. Medhora M, Gao F, Jacobs ER, Moulder JE. Radiation damage to the lung: mitigation by angiotensin-converting enzyme (ACE) inhibitors. Respirology 2012; 17(1): 66-71.
56. Pellmar TC, Rockwell S. Radiological/Nuclear Threat Countermeasures Working Group. Priority list of research areas for radiological nuclear threat countermeasures. Radiat Res 2005; 163(1): 115-23.
57. Aebersold P. FDA Experience with Medical Countermeasures under the Animal Rule. Adv Prev Med 2012; 2012: 507-71.
58. Thayer AM. The Drugs that may never be used. Chem Eng News 2012; 90(26): 23-26.
59. Fuccio L, Guido A, Andreyev HJ. Management of intestinal complications in patients with pelvic radiation disease. Clin Gastroenterol Hepatol 2012; 10: 1326-34.
60. Fuccio L, Guido A, Laterza L, et al. Randomised clinical trial: preventive treatment with topical rectal beclomethasone dipropionate reduces post-radiation risk of bleeding in patients irradiated for prostate cancer. Aliment Pharmacol Ther 2011; 34: 628-37.
61. Fuccio L, Guido A. Topical rectal beclomethasone dipropionate treatment for the prevention of radiation-induced bleeding. Gut 2012; 61(9): 1369.
62. Orrell RW. AEOL-10150 (Aeolus). Curr Opin Investig Drugs 2006; 7(1):70-80.
63. Copp RR, Peebles DD, Fahl WE. Synthesis and growth regulatory activity of a prototype member of a new family of aminothiol radioprotectors. Bioorg Med Chem Lett 2011; 21(24):7426-30.
64. Peebles DD, Soref CM, Copp RR, Thunberg AL, Fahl WE. ROSscavenger and radioprotective efficacy of the new PrC-210 aminothiol. Radiat Res 2012; 178(1):57-68.
65. Soref CM, Hacker TA, Fahl WE. A new orally active, aminothiol radioprotector-free of nausea and hypotension side effects at its highest radioprotective doses. Int J Radiat Oncol Biol Phys 2012; 82(5): e701-e707.